Measuring Urinary Nano Particles and Metallic Compounds in TCC Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02811952 |
Recruitment Status :
Completed
First Posted : June 23, 2016
Last Update Posted : October 14, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Bladder Cancer | Other: without intervention |
Study Type : | Observational |
Actual Enrollment : | 100 participants |
Observational Model: | Case-Control |
Time Perspective: | Prospective |
Official Title: | Measuring Urinary Nano Particles and Arsenic and Comparing Them to Cystoscopic Findings and Urinary Cytology in Patients Suspected With Urinary Bladder Malignancy |
Actual Study Start Date : | June 23, 2016 |
Actual Primary Completion Date : | July 31, 2020 |
Actual Study Completion Date : | January 1, 2021 |

Group/Cohort | Intervention/treatment |
---|---|
study group
Patients that need that need cystoscopy due to suspicion/known bladder malignancy.
|
Other: without intervention
without intervention |
control group
Patients that need cystoscopy due to others reasons than malignancy.
|
Other: without intervention
without intervention |
- levels of nano particles and arsenic in urine [ Time Frame: one year ]
Biospecimen Retention: Samples Without DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
Study group :
- Patients that need cystoscopy due to suspicion/known bladder malignancy.
- Patients that can read, understand and sign an informed consent form.
Control group:
- Patients that need cystoscopy due to others reasons than malignancy.
- Patients that present to the Department of Urology for surgery unrelated to malignancy of the urinary system ( prostatectomy, Incontinence repair, circumcision, hydrocele/ varicocele repair, ureteroscopy etc).
Exclusion Criteria:
Study group:
- Patients receiving bladder irrigations, pregnant women, children and those with impaired judgment
- Patients with a technically improper urine test.
Control group
- Patients receiving bladder irrigations, pregnant women, children and those with impaired judgment
- Patients with a technically improper urine test.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02811952
Israel | |
Carmel Lady Davis Medical Center | |
Haifa, Israel |
Responsible Party: | Ilan Beniamin Klein, urologist, Carmel Medical Center |
ClinicalTrials.gov Identifier: | NCT02811952 |
Other Study ID Numbers: |
CMC-15-0127-CTIL |
First Posted: | June 23, 2016 Key Record Dates |
Last Update Posted: | October 14, 2022 |
Last Verified: | October 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
bladder cancer |
Urinary Bladder Neoplasms Urologic Neoplasms Urogenital Neoplasms Neoplasms by Site |
Neoplasms Urinary Bladder Diseases Urologic Diseases |